Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc. (NASDAQ: VXRT), had cellular correlates of protection against influenza infection.1
These cellular correlates were found using mass cytometry analysis of vaccine-elicited cellular immune responses in the peripheral blood of participants in a previously reported Phase II H1N1 challenge study of VXA-A1.1.2
The U.S. Centers for Disease Control and Prevention (CDC) estimates that, on average, 36,000 people in the U.S. died from the flu in each of the past ten years. It is estimated that 61,000 people in the U.S. died from the flu in the 2017-2018 season – the highest toll in recent years. The 2019-2020 season, which was shorter than normal, resulted in approximately 22,000 U.S. deaths.3 Globally, the number of annual flu deaths has been estimated to range from nearly 300,000 to more than 600,000.4
“The data show that cellular responses are potentially more relevant for protection for an oral vaccine than circulating antibody responses,” said David McIlwain, Ph.D., senior research scientist in the Department of Microbiology and Immunology at the Stanford School of Medicine and lead author of the study.
“These results support using early immune response data to predict protection against respiratory pathogens several months later, potentially speeding vaccine development,” said Sean Tucker, Ph.D., Vaxart’s founder and chief scientific officer and a co-author of the publication.
About the Study
Results of a Phase II human influenza challenge study following vaccination with VXA-A1.1, which was funded by the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), have previously been reported.2 Participants in the Phase II study received either VXA-A1.1, an injected quadrivalent, inactivated influenza vaccine (IIV) or a placebo. Participants were challenged with H1N1 influenza virus 90-120 days after vaccination and were monitored for signs and symptoms of infection and viral shedding.
Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV. The results suggested that cellular responses rather than neutralizing antibodies may be especially important in the VXA-A1.1 mechanism of protection.2
The study announced today is the first to use mass cytometry to evaluate more than 40 different immune cell parameters in peripheral blood samples collected from 141 participants in the Phase II study. Mass cytometry immune cell profiling was performed on samples collected immediately prior to (day 1) and seven days following (day 8) vaccine administration.
Immune profiling tracked levels of multiple cell subsets with similar patterns of markers. The relationship between each subset and virus shedding was determined. Random forest-based machine learning models were used to define high-dimensional cellular correlates between the immune profiling and viral shedding data.
Key findings from the study include:
1 McIlwain D, Chen H, Rahil Z, et al. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host Microbe (2021). doi:10.1016/j.chom.2021.10.009
2 Liebowitz D, Gottlieb K, Kolhatkar NS et al. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect Dis. 2020;20:435-444.
3 USA Facts. How many people die from the flu? Available at: https://usafacts.org/articles/how-many-people-die-flu/
4 Paget J, Spreeuwenberg P, Charu V et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421.
Note Regarding Forward-Looking Statements
Session Details TBA
Continental Breakfast - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press
Growing Revenue: Services MSP Should Be Offering but May Not Know About